Stem cell gene therapy for fanconi anemia

Report from the 1st international fanconi anemia gene therapy working group meeting

Jakub Tolar, Jennifer E. Adair, Michael Antoniou, Cynthia C. Bartholomae, Pamela S. Becker, Bruce R. Blazar, Juan Bueren, Thomas Carroll, Marina Cavazzana-Calvo, D. Clapp, Robert Dalgleish, Anne Galy, H. Bobby Gaspar, Helmut Hanenberg, Christof Von Kalle, Hans Peter Kiem, Dirk Lindeman, Luigi Naldini, Susana Navarro, Raffaele Renella & 7 others Paula Rio, Julián Sevilla, Manfred Schmidt, Els Verhoeyen, John E. Wagner, David A. Williams, Adrian J. Thrasher

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Survival rates after allogeneic hematopoietic cell transplantation (HCT) for Fanconi anemia (FA) have increased dramatically since 2000. However, the use of autologous stem cell gene therapy, whereby the patient's own blood stem cells are modified to express the wild-type gene product, could potentially avoid the early and late complications of allogeneic HCT. Over the last decades, gene therapy has experienced a high degree of optimism interrupted by periods of diminished expectation. Optimism stems from recent examples of successful gene correction in several congenital immunodeficiencies, whereas diminished expectations come from the realization that gene therapy will not be free of side effects. The goal of the 1st International Fanconi Anemia Gene Therapy Working Group Meeting was to determine the optimal strategy for moving stem cell gene therapy into clinical trials for individuals with FA. To this end, key investigators examined vector design, transduction method, criteria for large-scale clinical-grade vector manufacture, hematopoietic cell preparation, and eligibility criteria for FA patients most likely to benefit. The report summarizes the roadmap for the development of gene therapy for FA.

Original languageEnglish
Pages (from-to)1193-1198
Number of pages6
JournalMolecular Therapy
Volume19
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Fanconi Anemia
Group Processes
Cell- and Tissue-Based Therapy
Genetic Therapy
Stem Cells
Cell Transplantation
Genes
Blood Cells
Survival Rate
Research Personnel
Clinical Trials

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Tolar, J., Adair, J. E., Antoniou, M., Bartholomae, C. C., Becker, P. S., Blazar, B. R., ... Thrasher, A. J. (2011). Stem cell gene therapy for fanconi anemia: Report from the 1st international fanconi anemia gene therapy working group meeting. Molecular Therapy, 19(7), 1193-1198. https://doi.org/10.1038/mt.2011.78

Stem cell gene therapy for fanconi anemia : Report from the 1st international fanconi anemia gene therapy working group meeting. / Tolar, Jakub; Adair, Jennifer E.; Antoniou, Michael; Bartholomae, Cynthia C.; Becker, Pamela S.; Blazar, Bruce R.; Bueren, Juan; Carroll, Thomas; Cavazzana-Calvo, Marina; Clapp, D.; Dalgleish, Robert; Galy, Anne; Gaspar, H. Bobby; Hanenberg, Helmut; Von Kalle, Christof; Kiem, Hans Peter; Lindeman, Dirk; Naldini, Luigi; Navarro, Susana; Renella, Raffaele; Rio, Paula; Sevilla, Julián; Schmidt, Manfred; Verhoeyen, Els; Wagner, John E.; Williams, David A.; Thrasher, Adrian J.

In: Molecular Therapy, Vol. 19, No. 7, 07.2011, p. 1193-1198.

Research output: Contribution to journalArticle

Tolar, J, Adair, JE, Antoniou, M, Bartholomae, CC, Becker, PS, Blazar, BR, Bueren, J, Carroll, T, Cavazzana-Calvo, M, Clapp, D, Dalgleish, R, Galy, A, Gaspar, HB, Hanenberg, H, Von Kalle, C, Kiem, HP, Lindeman, D, Naldini, L, Navarro, S, Renella, R, Rio, P, Sevilla, J, Schmidt, M, Verhoeyen, E, Wagner, JE, Williams, DA & Thrasher, AJ 2011, 'Stem cell gene therapy for fanconi anemia: Report from the 1st international fanconi anemia gene therapy working group meeting', Molecular Therapy, vol. 19, no. 7, pp. 1193-1198. https://doi.org/10.1038/mt.2011.78
Tolar, Jakub ; Adair, Jennifer E. ; Antoniou, Michael ; Bartholomae, Cynthia C. ; Becker, Pamela S. ; Blazar, Bruce R. ; Bueren, Juan ; Carroll, Thomas ; Cavazzana-Calvo, Marina ; Clapp, D. ; Dalgleish, Robert ; Galy, Anne ; Gaspar, H. Bobby ; Hanenberg, Helmut ; Von Kalle, Christof ; Kiem, Hans Peter ; Lindeman, Dirk ; Naldini, Luigi ; Navarro, Susana ; Renella, Raffaele ; Rio, Paula ; Sevilla, Julián ; Schmidt, Manfred ; Verhoeyen, Els ; Wagner, John E. ; Williams, David A. ; Thrasher, Adrian J. / Stem cell gene therapy for fanconi anemia : Report from the 1st international fanconi anemia gene therapy working group meeting. In: Molecular Therapy. 2011 ; Vol. 19, No. 7. pp. 1193-1198.
@article{589e95cf540840618c2d435118e11e64,
title = "Stem cell gene therapy for fanconi anemia: Report from the 1st international fanconi anemia gene therapy working group meeting",
abstract = "Survival rates after allogeneic hematopoietic cell transplantation (HCT) for Fanconi anemia (FA) have increased dramatically since 2000. However, the use of autologous stem cell gene therapy, whereby the patient's own blood stem cells are modified to express the wild-type gene product, could potentially avoid the early and late complications of allogeneic HCT. Over the last decades, gene therapy has experienced a high degree of optimism interrupted by periods of diminished expectation. Optimism stems from recent examples of successful gene correction in several congenital immunodeficiencies, whereas diminished expectations come from the realization that gene therapy will not be free of side effects. The goal of the 1st International Fanconi Anemia Gene Therapy Working Group Meeting was to determine the optimal strategy for moving stem cell gene therapy into clinical trials for individuals with FA. To this end, key investigators examined vector design, transduction method, criteria for large-scale clinical-grade vector manufacture, hematopoietic cell preparation, and eligibility criteria for FA patients most likely to benefit. The report summarizes the roadmap for the development of gene therapy for FA.",
author = "Jakub Tolar and Adair, {Jennifer E.} and Michael Antoniou and Bartholomae, {Cynthia C.} and Becker, {Pamela S.} and Blazar, {Bruce R.} and Juan Bueren and Thomas Carroll and Marina Cavazzana-Calvo and D. Clapp and Robert Dalgleish and Anne Galy and Gaspar, {H. Bobby} and Helmut Hanenberg and {Von Kalle}, Christof and Kiem, {Hans Peter} and Dirk Lindeman and Luigi Naldini and Susana Navarro and Raffaele Renella and Paula Rio and Juli{\'a}n Sevilla and Manfred Schmidt and Els Verhoeyen and Wagner, {John E.} and Williams, {David A.} and Thrasher, {Adrian J.}",
year = "2011",
month = "7",
doi = "10.1038/mt.2011.78",
language = "English",
volume = "19",
pages = "1193--1198",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Stem cell gene therapy for fanconi anemia

T2 - Report from the 1st international fanconi anemia gene therapy working group meeting

AU - Tolar, Jakub

AU - Adair, Jennifer E.

AU - Antoniou, Michael

AU - Bartholomae, Cynthia C.

AU - Becker, Pamela S.

AU - Blazar, Bruce R.

AU - Bueren, Juan

AU - Carroll, Thomas

AU - Cavazzana-Calvo, Marina

AU - Clapp, D.

AU - Dalgleish, Robert

AU - Galy, Anne

AU - Gaspar, H. Bobby

AU - Hanenberg, Helmut

AU - Von Kalle, Christof

AU - Kiem, Hans Peter

AU - Lindeman, Dirk

AU - Naldini, Luigi

AU - Navarro, Susana

AU - Renella, Raffaele

AU - Rio, Paula

AU - Sevilla, Julián

AU - Schmidt, Manfred

AU - Verhoeyen, Els

AU - Wagner, John E.

AU - Williams, David A.

AU - Thrasher, Adrian J.

PY - 2011/7

Y1 - 2011/7

N2 - Survival rates after allogeneic hematopoietic cell transplantation (HCT) for Fanconi anemia (FA) have increased dramatically since 2000. However, the use of autologous stem cell gene therapy, whereby the patient's own blood stem cells are modified to express the wild-type gene product, could potentially avoid the early and late complications of allogeneic HCT. Over the last decades, gene therapy has experienced a high degree of optimism interrupted by periods of diminished expectation. Optimism stems from recent examples of successful gene correction in several congenital immunodeficiencies, whereas diminished expectations come from the realization that gene therapy will not be free of side effects. The goal of the 1st International Fanconi Anemia Gene Therapy Working Group Meeting was to determine the optimal strategy for moving stem cell gene therapy into clinical trials for individuals with FA. To this end, key investigators examined vector design, transduction method, criteria for large-scale clinical-grade vector manufacture, hematopoietic cell preparation, and eligibility criteria for FA patients most likely to benefit. The report summarizes the roadmap for the development of gene therapy for FA.

AB - Survival rates after allogeneic hematopoietic cell transplantation (HCT) for Fanconi anemia (FA) have increased dramatically since 2000. However, the use of autologous stem cell gene therapy, whereby the patient's own blood stem cells are modified to express the wild-type gene product, could potentially avoid the early and late complications of allogeneic HCT. Over the last decades, gene therapy has experienced a high degree of optimism interrupted by periods of diminished expectation. Optimism stems from recent examples of successful gene correction in several congenital immunodeficiencies, whereas diminished expectations come from the realization that gene therapy will not be free of side effects. The goal of the 1st International Fanconi Anemia Gene Therapy Working Group Meeting was to determine the optimal strategy for moving stem cell gene therapy into clinical trials for individuals with FA. To this end, key investigators examined vector design, transduction method, criteria for large-scale clinical-grade vector manufacture, hematopoietic cell preparation, and eligibility criteria for FA patients most likely to benefit. The report summarizes the roadmap for the development of gene therapy for FA.

UR - http://www.scopus.com/inward/record.url?scp=79959919144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959919144&partnerID=8YFLogxK

U2 - 10.1038/mt.2011.78

DO - 10.1038/mt.2011.78

M3 - Article

VL - 19

SP - 1193

EP - 1198

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 7

ER -